About this collection

Recent Submissions

  • A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer. 

    Hamilton, Erika P; Patel, Manish R; Armstrong, Anne C; Baird, Richard Douglas; Jhaveri, Komal; Hoch, Matthias; Klinowska, Teresa et al. (American Association for Cancer Research, 2018-02-13)
    Purpose: AZD9496 is an oral nonsteroidal, small-molecule inhibitor of estrogen receptor alpha (ERα) and a potent and selective antagonist and degrader of ERα. This first-in-human phase I study determined the safety and ...
  • The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. 

    Weigelt, Britta; Bi, Rui; Kumar, Rahul; Blecua, Pedro; Mandelker, Diana L; Geyer, Felipe C; Pareja, Fresia et al. (OUP, 2018-02-28)
    Pathogenic germline variants in ataxia-telangiectasia mutated (ATM), a gene that plays a role in DNA damage response and cell cycle checkpoints, confer an increased breast cancer (BC) risk. Here, we investigated the ...
  • Stable centrosomal roots disentangle to allow interphase centriole independence 

    Mahen, Robert William (Public Library of Science (PLoS), 2018-04-12)
    The centrosome is a non–membrane-bound cellular compartment consisting of 2 centrioles surrounded by a protein coat termed the pericentriolar material (PCM). Centrioles generally remain physically associated together (a ...
  • Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. 

    Pashayan, Nora; Morris, Steve; Gilbert, Fiona; Pharoah, Paul David (2018-07-05)
    Abstract Importance The age-based or the ‘one-size-fits-all’ screening approach does not take into account the individual variation in risk. Mammography screening reduces death from breast cancer at a cost of overdiagnosis. ...

View more